Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

Patients with a manic episode or patients diagnosed with schizophrenia , patients who are being treated with quetiapine and are on a stable dosing regime

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

The patients who were considered for participation were patients who were being treated with quetiapine according to the Core Data Sheet and who were on a stable dosing regime. They could have been patients with schizophrenia or patients experiencing a manic episode associated with a bipolar disorder. Quetiapine was administered to the patients in regular practice.

You may qualify if:

The subjects should be considered eligible for this trail according to the physician:
Patients with a diagnose of schizophrenia or bipolar disorder with a recent manic episode
Patients who are being treated with quetiapine and are on an effective dose according to the Core Data Sheet; for schizophrenia between 300 and 450 mg (maximum 750 mg) and bipolar disorder between 400 and 800 mg.
Patients who consent to make the coded data available to AstraZeneca; provision of written informed consent

Sponsors & Collaborators

AstraZeneca
Industrylead

Study Sites (35)

Research Site

Almelo, Netherlands

Research Site

Alphen Aan de Rigjn, Netherlands

Research Site

Amersfoort, Netherlands

Research Site

Amstelveen, Netherlands

Research Site

Arnhem, Netherlands

Research Site

Bennebroek, Netherlands

Research Site

Beverwijk, Netherlands

MeSH Terms

Conditions

Bipolar DisorderSchizophrenia

Condition Hierarchy (Ancestors)

Bipolar and Related DisordersMood DisordersMental DisordersSchizophrenia Spectrum and Other Psychotic Disorders

Study Officials

N van Schayk
AstraZeneca
STUDY DIRECTOR

Enrollment

128 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

September 20, 2007

First Posted

September 21, 2007

Study Start

July 2007

Date type not reported

This date has not been verified as actual or estimated.

A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (35)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (35)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations